Results 61 to 70 of about 111,529 (192)

Novel Presentation of Homozygous Familial Hypercholesterolemia With Homozygous Variants in Both LDLR and APOB Genes

JACC: Case Reports, 2019
This case report describes a 50-year-old-woman from Southeast Asia with extensive atherosclerotic cardiovascular disease, found to have homozygous familial hypercholesterolemia caused by variants of uncertain significance in both the APOB and LDLR genes.
Robert Derenbecker, MD, Karan Kapoor, MD, Emily Brown, MGC, CGC, Thorsten Leucker, MD, PhD, Steven R. Jones, MD, Parvez M. Lokhandwala, MD, PhD, Kathleen H. Byrne, CRNP, Seth S. Martin, MD, MHS   +7 more
doaj   +1 more source

Is LDL apheresis a thing of the past?

South African General Practitioner, 2020
Patients with severe hypercholesterolaemia have a high lifetime risk for developing cardiovascular disease. These patients are traditionally treated with high-intensity statins and ezetimibe. Some patients are refractory to treatment and cannot achieve a desirable reduction in low-density lipoprotein cholesterol (LDL-C).
M Vally, R Khan, A Orchard
openaire   +2 more sources

DELP Treatment on Vision and Retinal Microcirculation in Patients With Acute Ischemic Stroke: Report of Five Cases and Literature Review

Therapeutic Apheresis and Dialysis, Volume 30, Issue 2, Page 168-175, April 2026.
ABSTRACT Background The delipid extracorporeal lipoprotein filter from plasma (DELP) treatment can effectively reduce blood lipid, increase blood flow, and improve neurological deficits in patients with acute ischemic stroke (AIS). However, its effect on vision and retinal microcirculation in stroke patients has never been reported.
Ning Li, Ronghua Hong, Hua You, Feiping Xu, Qingjun Zhang, Yiwen Lin, Yuting Su, Danmei Lan, Lingjing Jin, Junhui She   +9 more
wiley   +1 more source

Effects of Immunoadsorption on Markers of Iron Metabolism: A Case Series

Journal of Clinical Apheresis, Volume 41, Issue 2, April 2026.
ABSTRACT Immunoadsorption selectively eliminates circulating antibodies in antibody‐mediated diseases. Iron deficiency is the most common cause of anemia; however, the potential role of immunoadsorption in contributing to iron depletion remains insufficiently established.
Noemi E. Ginthör, Tobias Niedrist, Gerold Schwantzer, Alexander H. Kirsch, Werner Ribitsch, Andras Deak, Michael Kolland, Daniel Leitinger, Kathrin Eller, Alexander R. Rosenkranz, Katharina Artinger   +10 more
wiley   +1 more source

Apheresis In Developing Countries Around The World

, 2016
At the combined American Society for Apheresis (ASFA) Annual Meeting/World Apheresis Association (WAA) Congress in San Francisco, California, in April of 2014, the opening session highlighted the status of apheresis outside of the United States.
Jr.; Comenalli Marques, Robert; Naim, Norris; Mendrone, Jose Francisco, Quentin; Smid, Jr.; Marques, Eichbaum, W. Martin; Crookes, Marisa B., Alfredo   +9 more
core   +2 more sources

Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 4, April 2026.
ABSTRACT Background Studies comparing treatment strategies based on initiation timing—such as starting PCSK9 inhibitor (PCSK9i) therapy sooner versus later after a myocardial infarction (MI)—are prone to immortal time bias. Clone‐censor‐weight methods can address these issues and allow the researcher to emulate a trial in which patients are assigned to
Thomas Cars, Stefan Gustafsson, Queenie Chan, Nafeesa Dhalwani, Shia T. Kent, Andrew Briggs, Chris P. Gale, Anselm Gitt, J. Wouter Jukema, Philippe Gabriel Steg, Johan Sundström, Stefan James, Emil Hagström, M. Alan Brookhart   +13 more
wiley   +1 more source

Effects of weekly LDL-apheresis on metabolic parameters of apolipoprotein B in heterozygous familial hypercholesterolemia

Journal of Lipid Research, 1996
Apheresis is a treatment option for patients with severe hypercholesterolemia and coronary artery disease. It is, however, unknown whether such therapy changes kinetic parameters of lipoprotein metabolism, such as apolipoprotein B (apoB) secretion rates,
K G Parhofer, P H Barrett, T Demant, W O Richter, P Schwandt   +4 more
doaj   +1 more source

Building evidence for transfusion practice: A pilot study on bacterial adhesion and growth in red blood cell infusion sets

Transfusion, Volume 66, Issue 4, Page 689-699, April 2026.
Abstract Background Blood administration sets are changed after a prescribed time interval with variations in guidelines. In Canada, sets are changed every 4 h based on the theory of potential bacterial attachment. This study aimed to investigate whether bacteria adhere to the inner surfaces of blood administration sets during mimicked transfusions of ...
Zoya Versey, Yuntong Kou, Paula van Vliet, Donna L. Ledingham, Sandra Ramirez‐Arcos   +4 more
wiley   +1 more source

Efficiency and efficacy of LDL-apheresis performed at different intervals

, 1990
Five heterozygous familial hypercholesterolemia patients have been treated with LDL-apheresis for a period of three months. The apheretic procedure was repeated four times at both biweekly and weekly intervals.
L. Calabresi, G. Busnach, G. Franceschini, G. Chiesa   +3 more
core   +1 more source

Mathematical model for low density lipoprotein (LDL) endocytosis by hepatocytes [PDF]

, 2008
Individuals with elevated levels of plasma low density lipoprotein (LDL) cholesterol (LDL-C) are considered to be at risk of developing coronary heart disease.
B. O’Malley, J. A. D. Wattis, H. Blackburn, Wattis, JA, H. M. Byrne, L. Pickersgill, O'Malley, B, Panovska, J, Pickersgill, L, Blackburn, H, Byrne, HM, Byrne, Helen, K. G. Jackson, Wattis, JAD, Jackson, KG, J. Panovska, Panovska, J., O'Malley, B., Pickersgill, L., Wattis, J.A.D., Jackson, K.G., Blackburn, H., Byrne, H.M.   +22 more
core   +1 more source